Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1250-1255

  Baba, Masanori ^a   Okamoto, Mika ^a   Makino, Masahiko ^a   Kimura, Youichi ^b   Ikeuchi, Tohru ^b   Sakaguchi, Takanori ^c   Okamoto, Takashi ^c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PIPERAZINE DERIVATIVE; QUINOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CYTOTOXICITY; DRUG POTENCY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 0030995059     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1250     Document Type: Article

References (42)

1. Baba, M., E. De Clercq, H. Tanaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, K. Umezu, H. Nakashima, S. Mori, S. Shigeta, R. T. Walker, and T. Miyasaka. 1991. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 transcriptase. Proc. Natl. Acad. Sci. USA 88: 2356-2360.
2. + cell model of chronic infection. J. Virol. 65:4645-4653.
3. Butera, S. T., B. D. Roberts, J. W. Critchfield, G. Fang, T. McQuade, S. J. Gracheck, and T. M. Folks. 1995. Compound that target novel cellular components involved in HIV-1 transcription. Mol. Med. 1:758-767.
4. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
5. Critchfield, J. W., S. T. Butera, and T. M. Folks. 1996. Inhibition of HIV activation in latently infected cells by flavonoid compounds. AIDS Res. Hum. Retroviruses 12:39-46.
6. Cullen, B. R. 1991. Regulation of human immunodeficiency virus replication. Annu. Rev. Microbiol. 45:219-250.
7. De Clercq, E. 1995. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:200-239.
8. Duh, E. J., W. J. Maury, T. M. Folks, A. S. Fauci, and A. B. Rabson, 1989. Tumor necrosis factor α activates human immunodeficiency virus-1 through induction of a nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA 86:5974-5978.
9. Gendelman, H. E., W. Phelps, W. Feigenbaum, J. M. Ostrove, A. Adachi, P. M. Howley, G. Khoury, H. S. Ginsberg, and M. A. Martin. 1986. Transactivation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc. Natl. Acad. Sci. USA 83:9759-9763.
10. Gnabre, J. N., J. N. Brady, D. J. Clanton, Y. Ito, J. Dittmer, R. B. Bates, and R. C. C. Huang. 1995. Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence selective plant lignans. Proc. Natl. Acad. Sci. USA 92:11239-11243.
11. Griffin, G. E., K. Leung, T. M. Folks, S. Kunkel, and G. Nabel. 1989. Activation of HIV gene expression during monocyte differentiation by induction of NF-κB. Nature 339:70-73.
12. Hayashi, T., T. Sekine, and T. Okamoto. 1993. Identification of a new serine kinase that activates NF-κB by direct phosphorylation. J. Biol. Chem. 268: 26790-26795.
13. Hayashi, T., Y. Ueno, and T. Okamoto. 1993. Oxidoreductive regulation of nuclear factor κB. J. Biol. Chem. 268:11380-11388.
14. Hsu, M.-C., U. Dhingra, J. V. Earley, M. Holly, D. Keith, C. M. Nalin, A. R. Richou, A. D. Schutt, S. Y. Tam, M. J. Potash, D. J. Volsky, and D. D. Richman. 1993. Inhibition of type 1 human immunodeficiency virus replication by a Tat antagonist to which virus remains sensitive after prolonged exposure in vitro. Proc. Natl. Acad. Sci. USA 90:6395-6399.
15. Jones, K. A., and B. M. Peterlin. 1994. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:717-743.
16. Kalebic, T., A. Kinter, G. Poli, M. E. Anderson, A. Meister, and A. S. Fauci. 1991. Suppression of human immunodeficiency virus expression in chronically infected monocyte cells by glutathione, glutathione ester, and N-acetylcysteine. Proc. Natl. Acad. Sci. USA 88:986-990.
17. Kikukawa, R., Y. Koyanagi, S. Harada, N. Kobayashi, M. Hatanaka, and N. Yamamoto. 1986. Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J. Virol. 57:1159-1162.
18. Kimura, T., and O. Kogushi. December 1993. Aminoquinolone derivatives as anti-HIV agents. European patent 572259.
19. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-7134.
20. Leung, D. W., P. K. Peterson, R. Weeks, G. Gekker, C. C. Chao, A. H. Kaplan, N. Balantac, C. Tompkins, G. E. Underiner, S. Brusten, W. Harris, J. A. Bianco, and J. W. Singer. 1995. CT-2576, an inhibitor of phospholipid signaling, suppresses constitutive and induced expression of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 92:4813-4817.
21. Livington, D. J., S. Pazhanisamy, D. J. Porter, J. A. Partaledis, R. D. Tung, and G. R. Painter. 1995. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 172:1238-1245.
22. Miyoshi, I., H. Taguchi, I. Kubonishi, S. Yoshimoto, Y. Ohtsuki, Y. Shiraishi, and T. Akagi. 1982. Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr. 28:219-228.
23. Morse, H. C., III, S. K. Chattopadhyay, M. Makino, T. N. Frederickson, A. W. Hugin, and J. W. Hartley. 1992. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 6:607-620.
24. Nabel, G., and D. Baltimore. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326: 711-713.
25. Naumann, M., and C. Scheidereit. 1994. Activation of NF-κB in vivo is regulated by multiple phosphorylations. EMBO J. 13:4597-4607.
26. Okamoto, T. 1995. Regulatory proteins of human immunodeficiency virus and therapy, p. 117-127. In P. Mohan and M. Baba (ed.), Anti-AIDS drug development: challenges, strategies and prospects. Harwood Academic Publishers, Chur, Switzerland.
27. Okamoto, T., T. Maysuyama, S. Mori, Y. Hamamoto, N. Kobayashi, N. Yamamoto, S. J. Josephs, F. Wong-Staal, and K. Shimotohno. 1989. Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor α. AIDS Res. Hum. Retroviruses 5:131-138.
28. Okamoto, T., H. Ogiwara, T. Hayashi, A. Mitsui, T. Kawabe, and J. Yodoi. 1992. Human thioredoxin/adult T cell leukemia-derived factor activates the enhancer binding protein of human immunodeficiency virus type 1 by thiol redox control mechanism. Int. Immunol. 4:811-819.
29. Osborn, L. S., S. Kunkel, and G. J. Nabel. 1989. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl. Acad. Sci. USA 86:2336-2340.
30. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. A. C. Janssen, E. De Clercq, and P. A. J. Janssen. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474.
31. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
32. Perleson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
33. Prochaska, H. J., Y. Yeh, P. Baron, and B. Polski. 1993. Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 90:3953-3957.
34. Ratner, L., A. Fisher, L. L. Jagodzinski, H. Mitsuya, R. S. Liou, R. C. Gallo, and F. Wong-Staal. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses 3:57-69.
35. Roederer, M., F. J. T. Staal, P. A. Raju, S. W. Ela, L. A. Herzenberg, and L. A. Herzenberg. 1990. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc. Natl. Acad. Sci. USA 87:4884-4888.
36. Roulston, A., R. Lin, P. Beauparlant, M. A. Wainberg, and J. Hiscott. 1995. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-κB/Rel transcription factors. Microbiol. Rev. 59:481-505.
37. Schreiber, E., P. Matthias, M. M. Muller, and W. Schaffner. 1989. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17:6419.
38. Schutze, S., K. Potthoff, T. Machleidt, D. Berkovic, K. Wiegmann, and M. Kronke. 1992. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 71:765-776.
39. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
40. Subramani, S., R. Mulligan, and P. Berg. 1981. Expression of the mouse dihydrofolate reductase complementary deoxyribonucleic acid in simian virus 40 vectors. Mol. Cell. Biol. 2:854-864.
41. Wei, X., S. K. Ghosh, M. R. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
42. Witvrouw, M., R. Pauwels, A.-M. Vandamme, D. Schols, D. Reymen, N. Yamamoto, J. Desmyter, and E. De Clercq. 1992. Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. Antimicrob. Agents Chemother. 36:2628-2633.